Forward Pharma A/S (NASDAQ:FWP) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.
Several other analysts also recently issued reports on FWP. Jefferies Group LLC set a $22.00 price target on Forward Pharma A/S and gave the company a “hold” rating in a research note on Tuesday, April 18th. ValuEngine upgraded Forward Pharma A/S from a “sell” rating to a “hold” rating in a research note on Saturday, June 17th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $24.00.
Forward Pharma A/S (FWP) remained flat at $24.10 during midday trading on Thursday. 15 shares of the company traded hands. The company’s market capitalization is $1.14 billion. Forward Pharma A/S has a 12-month low of $14.89 and a 12-month high of $33.00. The stock has a 50-day moving average price of $21.81 and a 200-day moving average price of $23.38.
COPYRIGHT VIOLATION NOTICE: “Forward Pharma A/S (FWP) Rating Increased to Buy at BidaskClub” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/2797538/forward-pharma-as-fwp-rating-increased-to-buy-at-bidaskclub.html.
A number of hedge funds have recently added to or reduced their stakes in the stock. EcoR1 Capital LLC purchased a new stake in Forward Pharma A/S during the first quarter valued at about $108,000. Citadel Advisors LLC purchased a new stake in Forward Pharma A/S during the first quarter valued at about $269,000. NJ State Employees Deferred Compensation Plan purchased a new stake in Forward Pharma A/S during the first quarter valued at about $323,000. Eqis Capital Management Inc. purchased a new stake in Forward Pharma A/S during the first quarter valued at about $346,000. Finally, Marshall Wace North America L.P. purchased a new stake in Forward Pharma A/S during the first quarter valued at about $612,000. Institutional investors and hedge funds own 22.33% of the company’s stock.
Forward Pharma A/S Company Profile
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.